Melanoma vaccine to be tested in Melbourne, Australia

Main Category: Melanoma / Skin Cancer
Article Date: 07 Jun 2004 - 6:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


A medical team from Melbourne, Australia will head an international cancer trial. The phase two of vaccine trials to treat melanoma has been awarded to the Joint Austin Health Ludwig Institute - they will receive $870,000 to head the trial from a US cancer charity.

Jonathan Cebon, Associate Professor at the institute says the treatment works by targeting a molecule on cancer cells known as NY-ESO-1.

He said "We've got results that do excite us about how this vaccine affects the immune system. So the next step is to say okay, this is acting on the immune system, now what does that do to patients who have got cancer such as malignant melanoma. Does that activation of the immune system against this target NY-ESO-1 result in the cancer shrinking or perhaps disappearing?"

Article adapted by Medical News Today from original press release.
Visit our melanoma / skin cancer section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
n.p. "Melanoma vaccine to be tested in Melbourne, Australia." Medical News Today. MediLexicon, Intl., 7 Jun. 2004. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/9207.php>

APA
n.p. (2004, June 7). "Melanoma vaccine to be tested in Melbourne, Australia." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/9207.php.

Please note: If no author information is provided, the source is cited instead.


Melanoma / Skin Cancer

Most Popular Articles



Follow Our Melanoma News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Melanoma / Skin Cancer Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »